Assessing the pharmacokinetics and metabolism of [18F]LMI1195 in clinical imaging populations

Conclusions: These preliminary results suggest notable differences in the clearance and metabolic profiles of [18F]LMI1195 dependent on the given disease pathology. Radiotracer parent fraction can be equally measured by column-switching HPLC or SPE. These findings offer an important consideration for estimation of myocardial sympathetic nerve density using [18F]LMI1195 in patients suffering from cardiovascular disease. Support: Heart & Stroke Foundation of Canada/CANet ERLI (Rotstein) References: [1] Zelt, J. G. E. et al. J. Nucl. Cardiol. 2019, 26 (6), 2151-2153. [2] Sinusas, A. J. et al. J. Nucl. Med. 2014, 55 (9), 1445-1451. [3] Hilton, J. et al. Nucl. Med. Biol. 2000, 27 (6), 627-630.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Science (Poster Session) Source Type: research